Suppr超能文献

在埃塞俄比亚大学医院中,糖尿病患者血清肌酐翻倍时间:回顾性随访研究。

Time to doubling of serum creatinine in patients with diabetes in Ethiopian University Hospital: Retrospective follow-up study.

机构信息

Department of Clinical Pharmacy, School of Pharmacy, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.

出版信息

PLoS One. 2022 Sep 12;17(9):e0274495. doi: 10.1371/journal.pone.0274495. eCollection 2022.

Abstract

BACKGROUND

Diabetic kidney disease is one of the long-term microvascular complications of diabetes. Doubling of serum creatinine is an important biomarker and predictor of diabetic kidney disease for patients with diabetes. This study aimed to determine the time in which the serum creatinine level is doubled measured from the baseline in patients with diabetes in Ethiopian University Hospital.

METHODS

Analysis of the patients with diabetes medical records was employed retrospectively for five years from 2016 to 2020 in the University of Gondar Comprehensive Specialized Hospital. The Kaplan-Meier procedure was used to predict the time to which the serum creatinine level was doubled measured from the baseline value, while the Log-rank test and cox-proportional hazard regression models were employed to show significant serum creatinine (SCr) changes against the predictor variables.

RESULTS

Among the total of 387 patients with diabetes, 54.5% were females with a mean age of 61.1±10.3 years. After 5-years of retrospective follow-up, 10.3% of patients with diabetes had doubled their serum creatinine level computed from the baseline values. The baseline and last SCr levels (measured in mg/dL) were 0.87 (±0.23) and 1.0(±0.37), respectively. This resulted in a mean SCr difference of 0.12±0.38 mg/dL. The SCr score was continuously increasing uninterruptedly for five years and measured as 0.94, 0.95, 0.94, 1 and 1.03 mg/dL, respectively. The average survival time taken for the serum creatinine to be doubled computed from baseline was 55.4 months (4.6 years). Patients treated with greater than or equal to 30 IU NPH were found 3.3 times more likely to have higher risks of doubling the serum creatinine level (DSC); with HR of 3.29 [(95%CI); 1.28-8.44: P = 0.013].

CONCLUSION

Compared with the baseline level, a significant proportion of patients with diabetes were found to have doubling of serum creatinine DSC within less than five years around four and half years. A continuous increasing in the SCr level was noted when measured from the baseline scores. Therefore, to preserve the renal function of patients with diabetes, close SCr level monitoring and regular follow-up would be recommended in combined with effective therapeutic interventions.

摘要

背景

糖尿病肾病是糖尿病的一种长期微血管并发症。血清肌酐加倍是糖尿病患者糖尿病肾病的重要生物标志物和预测指标。本研究旨在确定在埃塞俄比亚大学医院的糖尿病患者中,从基线开始测量血清肌酐水平加倍所需的时间。

方法

对 2016 年至 2020 年在贡德尔大学综合专科医院的糖尿病患者病历进行了为期五年的回顾性分析。使用 Kaplan-Meier 程序预测从基线值开始测量的血清肌酐水平加倍所需的时间,而 Log-rank 检验和 Cox 比例风险回归模型则用于显示与预测变量相对应的显著血清肌酐 (SCr) 变化。

结果

在总共 387 名糖尿病患者中,54.5%为女性,平均年龄为 61.1±10.3 岁。经过 5 年的回顾性随访,有 10.3%的糖尿病患者的血清肌酐水平从基线值翻倍。基线和最后一次 SCr 水平(以 mg/dL 表示)分别为 0.87(±0.23)和 1.0(±0.37),这导致平均 SCr 差异为 0.12±0.38 mg/dL。SCr 评分连续五年不间断地升高,分别为 0.94、0.95、0.94、1 和 1.03 mg/dL。从基线开始计算血清肌酐翻倍所需的平均生存时间为 55.4 个月(4.6 年)。接受大于或等于 30IU NPH 治疗的患者发生血清肌酐翻倍的风险增加了 3.3 倍(DSC);风险比为 3.29[95%CI];1.28-8.44:P=0.013]。

结论

与基线水平相比,不到五年的时间内,约有四分之三的糖尿病患者发现血清肌酐 DSC 翻倍。从基线评分开始测量时,SCr 水平呈持续上升趋势。因此,为了保护糖尿病患者的肾功能,建议密切监测 SCr 水平并定期随访,并结合有效的治疗干预措施。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba14/9467309/1d29ac464961/pone.0274495.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验